Devyser Gains CE Mark for NGS Hereditary Breast and Ovarian Cancer Test

Mar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar

Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar

Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Menu

Devyser Gains CE Mark for NGS Hereditary Breast and Ovarian Cancer Test

To read the full story....

Breaking News

People in the News: New Appointments at Qiagen, ImmunoScape, 908 Devices, More

New Products Posted to GenomeWeb: Twist Bioscience, New England Biolabs, Promega, More

In Brief This Week: Thermo Fisher Scientific, Fourth Circuit Court of Appeals, Invitae, and More

GenDx HLA Genotyping Products Receives Health Canada IVD Approval

Personalis Q4 Revenues up 11 Percent

Natera Revenues Grow 35 Percent in Q4

Recent Headlines from
Precision Oncology News

Cartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment

Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors

CAR T-Cell Resistance Mechanism Shows Need for Multi-Antigen Targeted Immunotherapy Strategies

Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers

Fecal Transplants Boost Immunotherapy Response in Subset of Melanoma Patients

Featured White Papers

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

What's Popular?

ACMG Lobbying State Legislatures on Genetic Counselors' Scope of Practice Draws Criticism

Natera Revenues Grow 35 Percent in Q4

Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

Sponsorships